Abstract
Having a drug that works clinically, but without a clear mechanism, is like having a key that can be tried on many doors—eventually one will open, but what will be found? The paper by Burstein and colleagues (1) in this issue of Cephalalgia describes an unexpected connection between migraine and membrane trafficking associated with mechanical pain. In an elegant series of experiments, they show that onabotulinumtoxinA (BoNT-A) inhibits mechanical hyperalgesia, and proposed that it may act by preventing the insertion of mechanoreceptors at the plasma membrane. The authors used their well-established rat model of inflammatory agent-induced cranial pain to test the effect of BoNT-A on electrophysiological responses to mechanical stimulation. As an added bonus, they examined both intracranial and extracranial nociceptive branches of meningeal nociceptors, which was logical given that BoNT-A is injected extracranially. BoNT-A inhibited C-fiber responses to suprathreshold stimuli that could produce mechanical pain, but not responses to threshold non-pain stimuli. The remarkably long latency of hours for BoNT-A action is consistent with inhibition of mechanoreceptor translocation to the plasma membrane. This study is the first to test BoNT-A effects on nociceptive neurons believed to mediate migraine headache. As such, it takes us a step closer to understanding how this therapy may benefit migraine patients. While clinically proven effective for chronic migraine, the mechanism of action has been a mystery. Dogma predicted
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.